Click
Chat
 
Du kan vedhæfte PDF, JPG, PNG, DOC(X), XLS(X) og TXT-filer. Klik på ikonet, vælg fil og vent til upload er færdig før du indsender eller uploader endnu en fil.
60
Vedhæft Send
Historik

Vælg chat via ovenstående menu
Luk reklame

      

Arzerra salg op markant for kvartalet


61769 akademikeren 31/10 2012 13:04
Oversigt

Salget for q3 blev 19 mill pund. en del over forventninger til salget.

http://www.londonstockexchange.com/exchange/news/mark..

Oncology and emesis

Q3 2012 (£204 million; +8%)
Three new products, Votrient (up 70% to £49 million), Promacta (up 59% to £35 million) and Arzerra (up 58% to £19 million) all continued to grow in the US, Europe and EMAP. Tykerb/Tyverb fell 2% to £57 million, with growth in EMAP and Japan only partly offsetting declines in the US and Europe. Hycamtin continued to be adversely affected by generic competition in Europe.

In the US, Votrient (up 50% to £26 million) benefited from the launch of a new indication for use in advanced soft-tissue sarcoma. Sales of Promacta grew 50% to £15 million, reflecting the continued effect of longer-term use data that was added to the label in 2011.

9 months 2012 (£579 million; +17%)
Growth in the category in the nine months was driven by new products Votrient (up 80% to £121 million), Promacta (up 80% to £92 million) and Arzerra (up 44% to £46 million). Hycamtin sales fell 29% to £31 million as a result of generic competition in Europe.



31/10 2012 13:15 akademikeren 061770



Accelerende væksttrend i salget. Uptake er nu bedre end ritux....

GEN.CO




31/10 2012 13:17 akademikeren 061772



Her med det officielle salgstal. 171 mill DKK.

GEN.CO




TRÅDOVERSIGT